Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minodronate vs Alendronate in Postmenopausal Osteoporosis
NCT05305183Phase 3Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minodronic acid in postmenopausal osteoporosis (2 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Average rate of bone mineral density change of lumbar spine (L1-L4) at 48 weeks. Status: unknown.
02
Drugs
minodronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05305183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305183.